Barzilai Medical Center
Ashkelon, Israel
NCT Number: NCT07544342
The study is aimed to assess the risk factors for acquiring candida auris skin colonization during an outbreak in an ICU.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Ashkelon, Israel
Candida auris is unique when compared to other pathogenic fungi, as it spreads in the hospital rapidly. Therefore, it can cause healthcare-associated infections and outbreaks, it is resistant to antimicrobials and disinfectants and it is persisting on human skin and in the inanimate environment. There are few works listing factors found associated with candida auris candidemia, including longer CVC days, prior antibiotics, mechanical ventilation and longer ICU stay. Most of the research for candida auris risk factor doesn't differentiate colonization and infection, or, focuses on risk factors leading from colonization to infection. The study is aimed to assess the risk factors for acquiring candida auris skin colonization during an outbreak in an ICU.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From hospitalization in ICU until 2 weeks following discharge from ICU, a maximum of 90 days.
Positive screening for candida auris, taken by nose/ armpits and groin swabs and either directly seeded on a selective medium or by positive PCR.
Barzilai Medical Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07253311
Candida Auris Colonization, Candida Auris Infection
Athens, Greece
View Trial Details